ANALYSIS OF DRUG SUPPLY EXPENDITURES ON PATIENTS ON D MONITORING WITH GLOMERULAR DISEASE IN SHYMKENT

Received: 03.01.2025 Accepted: 06.02.2025 Published online: 27.02.2025
DOI: 10.53511/pharmkaz.2025.37.34.018
UDC 616-08-039.57
Ainur Assan1, Zakira Kerimbayeva2, Kemal Niyaz3, Ikilas Moldaliyev1,
Dmitry Sychev4, Abduzhappar Gaipov5
1 Department of Medicine, Khoja Akhmet Yassawi International Kazakh-Turkish University, Turkestan, Kazakhstan
2 Department of Public Health and Management, Astana Medical University, Astana, Kazakhstan
3 Department of Pharmaceutical Supply, Department of Healthcare of the City of Shymkent, Shymkent, Kazakhstan
4Department of Clinical Pharmacology and Therapy, Russian Medical Academy of Continuous Professional Education, Moscow,
Russian Federation
5 Department of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan
ANALYSIS OF DRUG SUPPLY EXPENDITURES ON PATIENTS
ON D MONITORING WITH GLOMERULAR DISEASE IN SHYMKENT
Introduction:
Glomerular diseases are a significant public health issue, often leading to chronic kidney disease (CKD) and increased
healthcare costs. Patients registered for D monitoring require continuous medication management, making drug supply
expenditures a critical aspect of treatment sustainability. Understanding the trends in drug expenditures can help optimize
resource allocation and improve patient outcomes.
Methods:
A retrospective analysis was conducted using data from the Information System for Outpatient Drug Supply Management
(ISLO) for patients with glomerular disease in Shymkent, Kazakhstan, from 2019 to 2023. The study examined the number of
prescriptions issued and the corresponding financial expenditures. Statistical trends were assessed to identify changes over
the study period.
Results:
The study revealed a significant increase in prescriptions from 2019 to 2020, followed by a consistent decline in subsequent
years. A similar trend was observed in financial expenditures, peaking in 2020 and decreasing thereafter. These fluctuations
suggest possible adjustments in healthcare policy, changes in patient registration, or variations in treatment protocols.
Discussion:
The findings indicate a potential reduction in healthcare resources allocated to glomerular disease management, despite the
increasing prevalence of CKD. The decline in expenditures could be attributed to cost-cutting measures, shifts in prescription
patterns, or limitations in drug supply. Ensuring sustainable healthcare financing is crucial to maintaining effective treatment
and preventing long-term complications.
Conclusion:
This study highlights the need for strategic resource allocation and consistent funding for outpatient drug supply programs.
Sustainable healthcare policies are essential to ensuring continued access to medications and improving the management of
glomerular diseases.
Keywords: glomerular disease, D monitoring, prescriptions, outpatient care, healthcare expenditures.

количество просмотров / 👁 9

Leave a Reply

Your email address will not be published. Required fields are marked *